---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-149338"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:44:31.015924+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty

## Summary
- J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.
- Seltorexant is a first-in-class orexin-2 receptor antagonist; no approved therapies exist for MDD with insomnia.
- Royalty Pharma is entitled to a mid-single-digit royalty on worldwide net sales of seltorexant.
- J&J previously estimated non-risk adjusted peak sales potential of $1B–$5B for seltorexant.

## SEC filing metadata
- accession: 0001193125-24-149338
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/0001193125-24-149338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/d34372d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-149338
- JSON: https://secwatch.observer/filing/0001193125-24-149338.json
- Plain text: https://secwatch.observer/filing/0001193125-24-149338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.